BridgeBio Pharma, Inc. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
BridgeBio Pharma, Inc. (BBIO) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $4.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-10
- BridgeBio Pharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $4.27M, a 113.88% increase year-over-year.
- BridgeBio Pharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $4.07M, a 129.39% increase year-over-year.
- BridgeBio Pharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-09-30 was $3.02M, a 109.63% increase year-over-year.
- BridgeBio Pharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-06-30 was $2.00M, a 14.46% increase year-over-year.
- BridgeBio Pharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $14.23M, a 89.02% increase from fiscal 2024.
- BridgeBio Pharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $7.53M, a 9.39% increase from fiscal 2023.
- BridgeBio Pharma, Inc. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $6.88M.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.27M 10-Q · filed 2026-08-10 | $8.34M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $4.07M 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $14.23M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $3.02M 10-Q · filed 2025-10-29 | $5.02M derived: sum of 2 quarters · filed 2026-08-10 | $6.80M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-06-30 | $2.00M 10-Q · filed 2026-08-10 | $3.77M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $1.78M 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $7.53M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $1.44M 10-Q · filed 2025-10-29 | $3.19M derived: sum of 2 quarters · filed 2025-10-29 | $6.12M derived: sum of 3 quarters · filed 2025-10-29 | |
| 2024-06-30 | $1.74M 10-Q · filed 2025-10-29 | $4.68M derived: sum of 2 quarters · filed 2025-10-29 | ||
| 2024-03-31 | $2.94M 10-Q · filed 2025-10-29 | |||
| 2023-12-31 | $6.88M 10-K · filed 2026-02-24 | |||
| 2023-06-30 | $1.20M 10-Q · filed 2023-11-02 | |||
| 2022-09-30 | $596.00K 10-Q · filed 2022-11-03 | $962.00K derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $366.00K 10-Q · filed 2023-11-02 | |||
| 2021-09-30 | $734.00K 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |